Business ❯ Finance ❯ Stock Market ❯ Company Performance

Investor Reactions

Alumis Shares Plunge After Phase 2b Lupus Trial Misses Primary Goal

A strong prespecified interferon‑high (IFNGS‑high) subgroup response gives the company a path to pursue a biomarker‑focused Phase 3.

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

Ferrari’s Luce Polarizes Public as Orders and Deliveries Move Forward

Open Standard Unveils Open USD With 140+ Corporate Backers

Ferrari’s First Electric Luce Draws Strong Backlash as CEO Says Orders Are Coming

Apple’s First Foldable Tipped as ‘iPhone Ultra’ for September Reveal

Snap Cuts 16% of Staff as AI Drives Restructuring

Hims Launches $49 Compounded Wegovy-Style Pill as Novo Vows Legal Action

Joby Sues Archer, Alleging Trade‑Secret Theft Tied to Ex‑Employee

Moonlake Shares Plunge on Mixed Phase 3 Results for Hidradenitis Drug